| Literature DB >> 35919032 |
Brehima Diakite1, Yaya Kassogue1, Mamoudou Maiga1,2,3, Guimogo Dolo1, Oumar Kassogue1, Jonah Musa2,3,4, Imran Morhason-Bello5, Ban Traore6, Cheick Bougadari Traore1, Bakarou Kamate1, Aissata Coulibaly1, Sekou Bah7, Sellama Nadifi8, Robert Murphy3, Jane L Holl9, Lifang Hou2,3.
Abstract
A literature review showed some discrepancies regarding the association of -592C/A with the risk of cervical cancer. To allow more precise analysis of the data by increasing the number of cases studied and more acceptable generalization by considering results from different sources, the present meta-analysis was performed on available published studies that explored the relationship between SNP-592C/A of the IL-10 gene and the risk of cervical cancer. Eleven available studies, including 4187 cases and 3311 controls, were included in this study investigating the relationship between the -592C/A polymorphism of IL-10 and cervical cancer risk. Fixed-effects or random-effects models were performed with pooled odds ratios (ORs). Heterogeneity and bias tests were performed by the inconsistency test and funnel plot, respectively. The overall analysis showed an increased susceptibility to cervical cancer with the -592C/A polymorphism of the IL-10 gene for the recessive model (OR = 1.30, 95% CI = 1.14-1.49), dominant model (OR = 1.36, 95% CI = 1.09-1.70), and additive model (OR = 1.25, 95% CI = 1.09-1.44). Regarding ethnicity, a significant association of the -592C/A polymorphism of the IL-10 gene was linked to an elevated risk of cervical cancer for all genetic models (recessive, dominant, and additive) in the Asian populations and for the recessive and additive models in Caucasians with P < 0.05. The -592C/A polymorphism of the IL-10 gene may be considered a risk factor for cervical cancer.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35919032 PMCID: PMC9296312 DOI: 10.1155/2022/2319161
Source DB: PubMed Journal: Genet Res (Camb) ISSN: 0016-6723 Impact factor: 1.375
Figure 1Flow diagram of eligible studies included.
Genotypic distribution of the IL-10-592C/A polymorphism in eligible studies.
| Author/year | Race/ethnicity | Cases | Controls | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| HWE | ||
| [ | Asian | 165 | 20 | 82 | 63 | 165 | 15 | 80 | 70 | 0.24 |
| [ | Asian | 240 | 49 | 133 | 58 | 204 | 65 | 111 | 28 | 0.07 |
| [ | Asian | 1044 | 380 | 522 | 142 | 1100 | 458 | 520 | 122 | 0.15 |
| [ | Caucasian | 1282 | 736 | 464 | 82 | 288 | 162 | 112 | 14 | 0.33 |
| [ | Caucasian | 85 | 24 | 50 | 11 | 146 | 68 | 62 | 16 | 0.74 |
| [ | Asian | 144 | 11 | 56 | 77 | 179 | 15 | 77 | 87 | 0.72 |
| [ | Asian | 200 | 16 | 96 | 88 | 200 | 17 | 102 | 81 | 0.05 |
| [ | Caucasian | 200 | 44 | 98 | 58 | 200 | 85 | 85 | 30 | 0.25 |
| [ | Asian | 70 | 12 | 23 | 35 | 108 | 13 | 44 | 51 | 0.46 |
| [ | Asian | 103 | 7 | 37 | 59 | 115 | 19 | 44 | 52 | 0.07 |
| [ | Caucasian | 654 | 393 | 231 | 30 | 606 | 405 | 175 | 26 | 0.20 |
N: number.
Genetic models and SNP-592C/A in the IL-10 gene in cervical cancer.
| Study |
| Cases/control | Models | Effect estimate/statistical | Bonferroni | Heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) |
|
| Sig |
|
| ||||
| All studies | 11 | 4187/3311 | |||||||
| Recessive | 1.30 (1.14–1.49) | 0.0001 | 0.016 | Yes | 28 | 0.18 | |||
| Dominant | 1.36 (1.09–1.70) | 0.006 | 0.016 | Yes | 66 | <0.05 | |||
| Additive | 1.25 (1.09–1.44) | 0.001 | 0.025 | Yes | 66 | <0.05 | |||
|
| |||||||||
| Caucasian | 4 | 2221/1240 | |||||||
| Recessive | 1.50 (1.12–2.00) | 0.006 | 0.016 | Yes | 39 | 0.18 | |||
| Dominant | 1.57 (1.03–2.40) | 0.04 | 0.016 | No | 84 | <0.05 | |||
| Additive | 1.15 (1.15–1.46) | <0.0001 | 0.025 | Yes | 81 | <0.05 | |||
|
| |||||||||
| Asian | 7 | 1966/2071 | |||||||
| Recessive | 1.25 (1.07–1.46) | 0.004 | 0.016 | Yes | 24 | 0.25 | |||
| Dominant | 1.26 (1.09–1.46) | 0.002 | 0.016 | Yes | 42 | 0.11 | |||
| Additive | 1.19 (1.08–1.30) | 0.0002 | 0.035 | Yes | 50 | 0.06 | |||
N: number; P: P value OR; P′: P value of heterogeneity; I2: inconsistency; recessive model: AA vs. CC + CA; dominant model: AA + CA vs. CC; additive model: A vs. C; = fixed-effect model, = random-effect model; N = number; α = Bonferroni correction; Sig = Bonferroni significance.
Figure 2Forest plots of the association between the -592C/A polymorphism of the IL-10 gene and cervical cancer for the (a) recessive model, (b) dominant model, and (c) additive model. The pooled OR is represented by a black diamond, the OR in each study is represented by blue squares with square sizes inversely proportionate to the standard error of the OR, and the horizontal lines represent the 95% CI.
Figure 3Forest plots of the association between SNP-592C/A in the IL-10 gene and cervical cancer for the (a) recessive model, (b) dominant model, and (c) additive model in the Caucasian population. The pooled OR is represented by a black diamond, the OR in each study is represented by blue squares with square sizes inversely proportionate to the standard error of the OR, and the horizontal lines represent the 95% CI.
Figure 4Forest plots of the association between the -592C/A polymorphism of the IL-10 gene and cervical cancer for the (a) recessive model, (b) dominant model, and (c) additive model in the Asian population. The black diamond represents the pooled OR, the blue squares show the OR in each study with square sizes inversely proportional to the standard error of the OR, and the horizontal lines denote the 95% CI.
Figure 5Funnel plots of the (a) recessive model, (b) dominant model, and (c) additive model precision by OR.
Figure 6Trial sequential analysis for IL10-592C/A polymorphism under the genotype contrast model. The x-axis shows the number of participants (cases and controls) of the meta-analysis in each branch. The y-axis z-score shows the z-score. The red line represents the required sample size. The green line represents the conventional test boundary (P=0.05).